ArticleDermatology and therapy2025
Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTralokinumab, a human IgG4 monoclonal antibody that inhibits the IL-13 pathway, is approved for the treatment of atopic dermatitis. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.
methodsThis retrospective study reviewed the Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and 16-20 weeks of 39 consecutive patients who received subcutaneous tralokinumab at the label dose in a tertiary centre.
resultsTwenty-nine out of 39 patients had an EASI score recorded after 16-20 weeks. At 16-20 weeks, 65.5% (19/29) of patients achieved EASI 50, 37.9% (11/29) achieved EASI 75, and 27.8% (9/29) achieved EASI 90. DLQI was reduced by an average of - 10.4 points at 16-20 weeks. No serious adverse events were reported. Ocular adverse events were reported in 25.6% (10/39) of the cohort but did not lead to treatment discontinuation. Six out of seven patients that previously experienced conjunctivitis with dupilumab had no recurrence with tralokinumab.
conclusionOur study supports using tralokinumab in atopic dermatitis with similar real-world efficacy to that shown in clinical trials. Tralokinumab offers an alternative for patients failing dupilumab because of conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.